Molecular design of Stat3-derived peptide selectivity between BET proteins Brd2 and Brd4 in ovarian cancer

Area of Science:

• Biochemistry
• Molecular Biology
• Oncology

Background:

• Signal transducer and activator of transcription 3 (Stat3) signaling is implicated in human ovarian cancer development.
• Stat3 interacts with BET family proteins Brd2 and Brd4, which regulate distinct downstream pathways.
• Targeting Stat3 signaling presents a potential therapeutic strategy for ovarian cancer.

Purpose of the Study:

• To design peptides with selectivity for Brd2 over the homologous protein Brd4.
• To investigate the structural basis for peptide-protein interactions and selectivity.

Main Methods:

• In silico design and in vitro validation of linear peptides.
• Assessing peptide selectivity using fold-change measurements.
• Structural analysis of peptide-protein interactions.

Main Results:

• Three linear peptides (SMSLQCXYLGVA, QSKVLTXSYWGA, RQCNLGXLYMNY) demonstrated high or moderate selectivity for Brd2 over Brd4.
• Peptide selectivity ranged from 3.3-fold to 6.8-fold, exceeding the native Stat3 peptide's selectivity (2.5-fold).
• N-terminus and hydrogen bonding interactions were identified as critical for peptide binding stability and specificity.

Conclusions:

• A rational design approach combining in silico and in vitro methods can achieve peptide selectivity between homologous proteins like Brd2 and Brd4.
• This methodology can be applied to develop targeted peptide ligands for therapeutic applications.
• The findings contribute to understanding Stat3 pathway regulation and offer potential avenues for ovarian cancer treatment.